Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis.
We studied the systemic absorption ot topical tobramycin and amikacin in experimental Pseudomonas keratitis in guinea pigs. After giving two drops of tobramycin 40 mg/ml every 30 minutes for 24 hours to both infected eyes (the corneal epithelium having removed) the mean serum concentration was 1.5 mcg/ml. Treatment of one of the infected eyes with the same strength of tobramycin or amikacin drops did not alter the number of viable bacteria in contralateral eyes treated with saline. Tobramycin 400 mg/ml or amikacin 250 mg/ml however, decreased the number of viable bacteria in the contralateral eyes. We conclude that the therapeutic effect on the contralateral eye was the result of systemic absorption.
D000042:Absorption; D000287:Administration, Topical; D000583:Amikacin / Q000008:administration & dosage* / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001682:Biological Availability; D003315:Cornea / Q000187:drug effects* / Q000382:microbiology; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D007612:Kanamycin / Q000031:analogs & derivatives*; D007634:Keratitis / Q000188:drug therapy*; D008297:Male; D009883:Ophthalmic Solutions; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D007612:Kanamycin; D000583:Amikacin; D014031:Tobramycin